|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||
| Investments at fair value: | ||||||||||||||
| Cash and cash equivalents | ||||||||||||||
| Collateral receivable on forward currency exchange contracts | ||||||||||||||
| Interest receivable | ||||||||||||||
| Deferred offering costs | ||||||||||||||
| Receivable for issuance of common shares | ||||||||||||||
| Unrealized appreciation on foreign currency forward contracts | ||||||||||||||
| Receivable for investments sold | ||||||||||||||
| Other assets | ||||||||||||||
| Total assets | ||||||||||||||
| LIABILITIES | ||||||||||||||
| Payable for investments purchased | ||||||||||||||
| Collateral payable on forward currency exchange contracts | ||||||||||||||
| Management fees payable | ||||||||||||||
| Income incentive fee payable | ||||||||||||||
| Capital gains incentive fee payable | ||||||||||||||
| Board of Managers fee payable | ||||||||||||||
| Distribution payable | ||||||||||||||
| Unrealized depreciation on foreign currency forward contracts | ||||||||||||||
| Accrued expenses and other liabilities | ||||||||||||||
| Total liabilities | ||||||||||||||
| NET ASSETS | ||||||||||||||
| Common shares, $0.01 par value (44,724,135 and 44,724,135 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively) | ||||||||||||||
| Additional paid in capital | ||||||||||||||
| Distributable earnings (loss) | ||||||||||||||
| Total net assets | ||||||||||||||
| Total liabilities and net assets | ||||||||||||||
| Net asset value per share (in dollars per share) |
Loading...
